Thursday 16 October, 2025
Objectives: Individual prediction-based dose adaptation (IPBDA) method using an ordinal data model of toxicity has been developed for anticancer drug…
Read moreOral: Clinical Applications
These abstracts are expected to deal with applications of pharmacometrics whose aim is to improve individual patient treatment. They may include studies that have identified covariates that can be applied to calculate the dose, or even better, if the application was able to take patient response (concentration, biomarker) and further improve the individual dose. They can include simulation studies that explore how to improve patient treatment by dose individualization. The abstract must indicate an algorithm demonstrating how an individual patient dose is calculated.
Evaluation of the antitumor effect of PCV chemotherapy on low-grade gliomas patients with a longitudinal tumor growth inhibition model
Thursday 16 October, 2025
Objectives: To develop a tumor growth inhibition model able to describe the evolution of diffuse low-grade gliomas (LGGs) growth dynamics…
Read morePKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3 and sKIT as Biomarkers of Tumor Response and Overall Survival Following Sunitinib Treatment in GIST
Thursday 16 October, 2025
Objectives: The aim of the present study was to investigate potential biomarker relationships for tumor response and treatment outcome (overall…
Read moreComposite Importance Sampling (CIS) for continuous learning in precision dosing
Thursday 16 October, 2025
Introduction: Continuous learning (CL) in model-informed precision dosing (MIPD) can improve accuracy in forecasting and dosing advice.[1,2,3] CL leverages data…
Read moreDetermination of effective blood concentrations of cyclosporine in pediatric severe aplastic anemia based on a time-to-response model
Thursday 16 October, 2025
Objectives: Optimal immunosuppressive therapy in acquired severe aplastic anemia (SAA), a rare disease affecting children, remains to be defined. Current recommendations…
Read moreUsing a model based approach to inform dose escalation in a Ph I Study by combining emerging clinical and prior preclinical information: an example in oncology
Thursday 16 October, 2025
Objectives: Oncology Phase I studies are typically small, open-label, sequential studies enrolling 3-6 patients per dose escalation [1]. Deriving a…
Read morePKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin – What is the optimal testosterone level?
Thursday 16 October, 2025
Objectives: The main goal in the treatment of prostate cancer with gonadotropin-releasing hormone (GnRH) agonists is to achieve and maintain…
Read moreUsing pharmacokinetic simulation to guide dose escalation decisions for targeted IL2v immunocytokines
Thursday 16 October, 2025
Objectives: To guide dose escalation of targeted IL2v compounds with a narrow safety window through pharmacokinetic (PK) simulation, when a…
Read moreTime-to-Event Modeling of Peripheral Neuropathy – Platform Mega-Analysis of Eight vc-MMAE Antibody-Drug Conjugates (ADCs)
Thursday 16 October, 2025
Objectives: valine-citrulline-MMAE (vc-MMAE) ADCs are the most commonly used linker-drug combinations in the ADC platform currently under clinical investigation. Peripheral neuropathy…
Read moreSemi-physiologic population PKPD model characterizing the effect of bitopertin (RG1678) glycine reuptake inhibitor on hemoglobin turnover in humans
Thursday 16 October, 2025
Objectives: Bitopertin, a glycine reuptake inhibitor in development for the treatment of schizophrenia, selectively inhibits the glycine transporter type 1…
Read more